Article Text

other Versions

PDF
Safety of measles, mumps and rubella vaccination in Juvenile Idiopathic Arthritis
  1. Marloes W Heijstek (mwheijstek{at}hotmail.com)
  1. Dept Paed Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Netherlands
    1. Cecilmare Pileggi (fmpileggi{at}terra.com.br)
    1. Dept Paed Rheumatology and immunology, School of Medicine of Ribeirão Preto, Univ of Sao Pau, Brazil
      1. Evelien Zonneveld-Huijssoon (e.zonneveld-huijssoon{at}umcutrecht.nl)
      1. Dept of Paed Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Netherlands
        1. Wieneke Armbrust (w.armbrust{at}bkk.azg.nl)
        1. Dept of Paed Rheumatolgy, Beatrix Children’s Hospital, University Medical Centre Groningen, Netherlands
          1. Esther PAH Hoppenreijs (e.hoppenreijs{at}cukz.umcn.nl)
          1. Dept Paediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
            1. Cuno SPM Uiterwaal (c.s.p.m.uiterwaal{at}umcutrecht.nl)
            1. Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Netherlands
              1. Wietse Kuis (w.kuis{at}umcutrecht.nl)
              1. Dept of Paed Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Netherlands
                1. Nico M Wulffraat (n.wulffraat{at}umcutrecht.nl)
                1. Dept of Paed Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Netherlands

                  Abstract

                  Objective: To assess the effect of measles, mumps and rubella (MMR) vaccination on disease activity in children with Juvenile Idiopathic Arthritis (JIA).

                  Methods: A retrospective observational multicenter cohort study was performed in 314 JIA patients, born between 1989 and 1996. Disease activity and medication use were compared during the period of six months before versus six months after vaccination. Disease activity was measured by joint counts, physician’s global assessment and ESR. Next, we compared disease activity in patients vaccinated between 8 and 9 years of age with the activity in not yet vaccinated patients, who received MMR between age 9 and 10.

                  Results: No deterioration in disease activity and medication use was seen in the six months after MMR vaccination (n=207). This was also true for patients using methotrexate (n=49). No overt measles infections were noted. When disease activity in early vaccinated patients (n=108) was compared to activity in not yet vaccinated patients (n=86), there were no statistically significant differences.

                  Conclusions: The MMR booster vaccination seems not to aggravate JIA disease activity. This indicates that the majority of patients with JIA can be vaccinated safely with the measles, mumps and rubella vaccine. A prospective study is recommended.

                  • Juvenile Idiopathic Arthritis
                  • Measles, Mumps and Rubella vaccination
                  • disease activity parameters
                  • flares
                  • methotrexate

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.